Welgene Biotech Co.,Ltd.

Taipei Exchange 6661.TWO

Welgene Biotech Co.,Ltd. Market Capitalization on January 14, 2025: USD 17.12 M

Welgene Biotech Co.,Ltd. Market Capitalization is USD 17.12 M on January 14, 2025, a 0.46% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Welgene Biotech Co.,Ltd. 52-week high Market Capitalization is USD 26.91 M on July 22, 2024, which is 57.23% above the current Market Capitalization.
Welgene Biotech Co.,Ltd. 52-week low Market Capitalization is USD 15.86 M on April 16, 2024, which is -7.32% below the current Market Capitalization.
Welgene Biotech Co.,Ltd. average Market Capitalization for the last 52 weeks is USD 17.96 M.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

Taipei Exchange: 6661.TWO

Welgene Biotech Co.,Ltd.

CEO	Dr. Yi Xing Lin
IPO Date	Oct. 23, 2017
Location	Taiwan
Headquarters	No. 3, Yuanyuan Street
Employees	80
Sector	Health Care
Industries Biotechnology Research & Consulting

Description

Welgene Biotech Co.,Ltd. provides genetic testing services. The company offers research services, including sequencing, microarray, qPCR verification, nucleic acid extraction/QC, LCM single cell experiment, and bioinformatics analysis services; and Cytoscan, an array-based comparative genomic hybridization. It also provides reagents, consumable supplies, and instruments, as well as software services. The company was founded in 2003 and is based in Taipei City, Taiwan.

Key trends

Past 5 years